sufentanil-induced coughing
Conditions
Interventions
TG group:TG Group Patients:
1.Tegileridine Administration: Administer 0.75 mg of Tegileridine intravenously as an initial dose.
2.Sufentanil Administration: Within 15 seconds after the Tegileridine in
NS group:NS Group Patients:
1.Normal Saline Administration: Administer 0.75 mL of normal saline (0.9% sodium chloride solution) intravenously as an initial bolus.
2.Sufentanil Administration: Within 1
Sponsors
Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 years <= participant age <= 70 years; 2.ASA Physical Status Classification: ASA I-III ; 3.Surgical Plan: Scheduled elective surgery requiring general anesthesia .
Exclusion criteria
Exclusion criteria: 1.severe hepatic and renal insufficiency; 2.chronic administration of opioids; 3.a history of respiratory diseases, such as asthma, chronic cough, chronic obstructive pulmonary disease (COPD),and upper respiratory tract infection within two weeks; 4.recently used bronchodilator; steroid therapy;angiotensin converting enzyme inhibitor(ACEI) ; 5.allergy to Tegileridine; 6.predicted difficult airway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cough within 1 min after sufentanil injection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of cough;Hemodynamic changes during induction; | — |
Countries
China
Contacts
Public ContactYang Liqun
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed